Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults aged ≥ 40 years, who have signed an informed consent form prior to initiation of any study-related procedure.~* Co-operative outpatients with a diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD), as classified by the GOLD Guidelines (2006), and:~  * Smoking history of at least 20 pack years.~ * Post-bronchodilator forced expiratory volume in 1 second (FEV1) \< 80% and ≥ 30% of the predicted normal value.~ * Post-bronchodilator FEV1/forced vital capacity (FVC) \< 70%.~Exclusion Criteria:~* Pregnant or nursing (lactating) women.~* Women of child-bearing potential.~* Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period.~* Patients requiring oxygen therapy or who experience oxygen desaturation to \< 80% during cycle exercise on room air.~* Patients with a Wmax value \< 20 W (as determined by the incremental cycle endurance test) at screening.~* Patients who have had a respiratory tract infection within 6 weeks prior to screening.~* Patients with contra-indications of cardiopulmonary exercise testing.~* Patients with concomitant pulmonary disease.~* Patients with a history (up to and including the screening visit) of asthma.~* Patients with diabetes Type I or uncontrolled diabetes Type II.~* Any patient with lung cancer or a history of lung cancer.~* Any patient with active cancer or a history of cancer with less than 5 years disease free survival time.~* Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at the collection of informed consent visit (Visit 1) or randomization is prolonged.~* Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period.~* Patients unable to successfully use a dry powder inhaler device, metered dose inhaler (MDI), or perform spirometry measurements.~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 300 μg followed by placebo (Type: EXPERIMENTAL): Patients first received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received placebo delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
- Placebo followed by indacaterol 300 μg (Type: EXPERIMENTAL): Patients first received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received indacaterol 300 μg delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).